Status:
COMPLETED
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
Lead Sponsor:
AstraZeneca
Conditions:
GERD
Acid Reflux Disease
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).
Eligibility Criteria
Inclusion
- Subject able to read and write US english and able to use electronic devices
- Subjects who have experienced GERD symptoms for at least six months
- Subjects currently taking a prescription or over-the-counter PPI medications for GERD
- Body Mass Index (BMI) 18.5-35.0, inclusive
Exclusion
- Subjects that have not experienced any GERD symptoms improvement at all after PPI treatment
- Subjects who have any of the following conditions or diseases- Heart disease, Angina, Seizure disorders such as epilepsy, Congestive Heart Failure (CHF), Liver disease such as Cirrhosis or Hepatitis, Kidney disease, Lung disease or lung cancer, Cancer
- Prior surgery of the upper Gastrointestinal (GI) tract
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
478 Patients enrolled
Trial Details
Trial ID
NCT00703534
Start Date
May 1 2008
End Date
January 1 2009
Last Update
June 20 2011
Active Locations (84)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Athens, Alabama, United States
2
Research Site
Tucson, Arizona, United States
3
Research Site
Little Rock, Arkansas, United States
4
Research Site
Sherwood, Arkansas, United States